A study released Friday found that kid-size doses of Pfizer’s Covid vaccine are nearly 91 percent effective at preventing symptomatic infections in 5- to 11-year-olds.
Related Articles
-
CDC says racism is a ‘serious threat’ to public health
The Centers for Disease Control and Prevention on Thursday called racism a “serious threat” to public health, becoming the...
-
Covid rapid tests are cheap or free in other countries. Why do Americans pay so much?
Rapid at-home Covid-19 tests are flying off store shelves across the country and are largely sold out online as...
-
Will the Covid vaccine be safe? What the scientists want to see
The first experimental coronavirus vaccines could be available by the end of the year, and while that’s welcome news...
-
Covid hospitalization hot spots across the U.S., in five charts
Covid-19 hospitalizations are once again ticking upward after a lull in October and early November, with tens of thousands...
-
HHS official takes leave of absence after rant about CDC conspiracies
The top spokesman for the Department of Health and Human Services is taking a leave of absence, the agency...
-
IV fluid supply crunch forces hospitals to postpone elective surgery
A limited supply of IV fluid, stemming from damage caused by Hurricane Helene, is forcing some hospitals across the...
-
Risk of heart issues from Covid infection greater than from vaccination, CDC finds
Compared to vaccination, Covid-19 itself is far more likely to lead to heart problems in teenage boys and young...
-
Pfizer asks FDA to authorize Covid antiviral pills
Pfizer asked the Food and Drug Administration on Tuesday to authorize its experimental Covid-19 antiviral treatment, Paxlovid. The treatment...
Recent Comments